HUP0003428A2 - Leptin antagonisták alkalmazása diabetes kezelésére - Google Patents

Leptin antagonisták alkalmazása diabetes kezelésére

Info

Publication number
HUP0003428A2
HUP0003428A2 HU0003428A HUP0003428A HUP0003428A2 HU P0003428 A2 HUP0003428 A2 HU P0003428A2 HU 0003428 A HU0003428 A HU 0003428A HU P0003428 A HUP0003428 A HU P0003428A HU P0003428 A2 HUP0003428 A2 HU P0003428A2
Authority
HU
Hungary
Prior art keywords
treatment
diabetes
leptin
leptin antagonists
well
Prior art date
Application number
HU0003428A
Other languages
English (en)
Inventor
Michael Anthony Cawthorne
Valur Emilsson
Yong-Ling Liu
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of HUP0003428A2 publication Critical patent/HUP0003428A2/hu
Publication of HUP0003428A3 publication Critical patent/HUP0003428A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány egy leptin antagonista hiányos inzulinszekrécióbólszármazó rendellenességek és hyperglyakemia, valamintinzulinrezisztencia kezelésére szolgáló gyógyszerkészítményekelőállítására történő alkalmazására vonatkozik. A találmány kiterjedaz említett gyógyszerkészítményekre, valamint a fenti rendellenességekés betegségek leptin antagonistákkal végzett kezelési eljárásaira is. Ó
HU0003428A 1997-06-06 1997-06-06 Use of leptin antagonists for the treatment of diabetes HUP0003428A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1997/002240 WO1998055139A1 (en) 1997-06-06 1997-06-06 Use of leptin antagonists for the treatment of diabetes

Publications (2)

Publication Number Publication Date
HUP0003428A2 true HUP0003428A2 (hu) 2001-05-28
HUP0003428A3 HUP0003428A3 (en) 2001-12-28

Family

ID=8166613

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003428A HUP0003428A3 (en) 1997-06-06 1997-06-06 Use of leptin antagonists for the treatment of diabetes

Country Status (9)

Country Link
EP (1) EP0986397A1 (hu)
JP (1) JP2002504102A (hu)
KR (1) KR20010013414A (hu)
AU (1) AU2951797A (hu)
CA (1) CA2293504A1 (hu)
HU (1) HUP0003428A3 (hu)
IL (1) IL133136A0 (hu)
TR (1) TR199902980T2 (hu)
WO (1) WO1998055139A1 (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
KR20120034237A (ko) 2004-02-11 2012-04-10 아밀린 파마슈티칼스, 인크. 선택가능한 특성을 갖는 하이브리드 폴리펩티드
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
JP2012523434A (ja) 2009-04-10 2012-10-04 アミリン・ファーマシューティカルズ，インコーポレイテッド エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物
CA2813038C (en) 2010-09-28 2021-12-28 Amylin Pharmaceuticals, Llc Highly soluble leptins
JP6040464B2 (ja) 2011-07-08 2016-12-07 アエゲリオン・ファーマシューティカルズ・インコーポレイテッドＡｅｇｅｒｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
HUE040496T2 (hu) 2012-09-27 2019-03-28 Childrens Medical Ct Corp Vegyületek elhízás kezelésére és alkalmazási eljárásaik
RS58422B1 (sr) 2013-11-26 2019-04-30 Childrens Medical Ct Corp Jedinjenja za tretiranje gojaznosti i postupci za njihovu upotrebu
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
FI3509624T3 (fi) 2016-09-12 2023-10-18 Amryt Pharmaceuticals Inc Menetelmiä neutraloivien anti-leptiini -vasta-aineiden havaitsemiseksi

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
IL122718A0 (en) * 1995-06-30 1998-08-16 Lilly Co Eli Methods for treating diabetes

Also Published As

Publication number Publication date
AU2951797A (en) 1998-12-21
JP2002504102A (ja) 2002-02-05
TR199902980T2 (xx) 2000-05-22
IL133136A0 (en) 2001-03-19
EP0986397A1 (en) 2000-03-22
WO1998055139A1 (en) 1998-12-10
HUP0003428A3 (en) 2001-12-28
CA2293504A1 (en) 1998-12-10
KR20010013414A (ko) 2001-02-26

Similar Documents

Publication Publication Date Title
HUP0003428A2 (hu) Leptin antagonisták alkalmazása diabetes kezelésére
EA200000747A1 (ru) СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
BR0311313A (pt) Derivados de diaril uréia úteis para o tratamento de doenças dependentes de proteìna cinase
HUP0002373A2 (hu) Glükagon antagonisták/inverz agonisták és ezeket tartalmazó gyógyászati készítmények
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
MXPA04011612A (es) Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
HUP9904362A2 (hu) Eljárás felső légúti allergiás tünetek kezelésére hisztamin H1 és H3 receptor-antagonisták kombinációjával
NO963568D0 (no) Farmasöytisk preparat for behandling av blodkoagulasjonssykdommer, fremgangsmåter for fremstilling av dette og dets anvendelse
WO2003004480A3 (en) Substituted piperazine and diazepanes as histamine h3 receptor agonists
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
HUP0102193A2 (hu) Glukagonszerű peptid-1, mely a béta-sejtek glükózra adott válaszát glükóz toleranciában sérült személyeknél javítja
WO2003062273A3 (en) Modulator of the notch signalling pathway and use thereof in medical treatment
DK0979079T3 (da) Anvendelse af tetrahydropyridinderivater til fremstilling af lægemidler til behandling af sygdomme, der medförer en demyelinisering
DE69814394D1 (de) Verwendung von levobupivacain
ATE231849T1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
WO2006012603A3 (en) Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases
IS1910B (is) Notkun á fankínóni til meðhöndlunar á Alzheimers-sjúkdómi
SG160197A1 (en) Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
WO2002069944A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und nk1-rezeptor-antagonisten
HUP0302293A2 (hu) Rák kezelése aplidin és egy izomvédő szer együttes alkalmazásával
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
ATE229336T1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
HUP0103017A3 (en) Pharmaceutical composition for the treatment of diseases caused by impairment of cognitive functions and its use